| Marian Hospice 504/506 E Plaza Dr, Santa Maria, CA, 93454 | |
| (805) 739-3830 |
News Archive
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.
Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
› Verified 8 days ago
| Name | Marian Hospice |
|---|---|
| Location | 504/506 E Plaza Dr, Santa Maria, California |
| Hospice ID | 051592 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 520 |
News Archive
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.
Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
› Verified 8 days ago
| NPI Number | 1821134040 |
| Organization Name | Dignity Health |
| Address | 124 S College Dr Santa Maria, California, 93454 |
| Phone Number | (805)739-3830 |
News Archive
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.
Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 99.8 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 85.8 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 99.4 | 93.3 |
News Archive
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.
Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
› Verified 8 days ago
| Home Health Aides | 11 |
| Counselors | 1 |
| Homemakers | 2 |
| Licensed Practical or Vocational Nurses | 1 |
| Medical Social Workers | 4 |
| Registered Nurses | 24 |
| Other Personnel | 4 |
| Total Employees | 47 |
|---|
News Archive
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.
Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
› Verified 8 days ago
| Marian Hospice Location: 504/506 E Plaza Dr, Santa Maria, California, 93454 Phone: (805) 739-3830 |